-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis. Biochemical Pharmacology, Elsevier, 2010, 81 (1) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 2
3

Introduction:
The non-steroidal anti-inflammatory drug Celecoxib (Cerebrex®) is a specific inhibitor of cyclooxygenase-2 (COX-2) with anti-neoplastic properties [1] . COX-2 is involved in prostaglandin production during the inflammatory response [2] . The enzyme is also overexpressed in many human tumors and contributes to tumorigenesis [3] . Thus, in addition to their anti-inflammatory activities, coxibes might interfere with tumor progression [4, 5] .
Previous experiments in COX-2-negative cell lines and with Celecoxib derivates lacking the COX-2 inhibitory function indicate that Celecoxib might have yet other targets through which it exerts cytotoxic effects [6] [7] [8] [9] [10] . We have recently shown that Celecoxib induced apoptosis through the intrinsic pathway [11] [12] [13] . This apoptotic pathway involves permeabilization of the outer mitochondrial membrane and the dissipation of mitochondrial membrane potential [14, 15] . Apoptogenic factors which are found in the mitochondrial intermembrane space of healthy cells are released into the cytosol where they facilitate the activation of caspases, the executers of the apoptotic death program.
Members of the Bcl-2 protein family are the gate keepers of the mitochondrial homeostasis regulating the release of pro-apoptotic factor from the mitochondrial intermembrane space into the cytosol. The Bcl-2 protein family consists of pro-and anti-apoptotic members which are able to form heterodimers [16, 17] . Among others, the anti-apoptotic group encompasses Bcl-2, Bcl-xL, Mcl-1, and A1 which are often found to be over-expressed in tumor tissues.
The pro-apoptotic group is divided in multi-domain proteins (Bax, Bak, Bok) which share three Bcl-2 homologous domains (BH1-3) and the BH3-only proteins (Bim, Bid, Puma, Bad, Bik, Bmf, Noxa) which have only the BH3 domain in common.
The activation of the multi-domain proteins is absolutely essential for mitochondrial permeabilization and apoptosis induction. Currently, two theories exist which explain the involvement of the different anti-apoptotic and BH3-only proteins leading to activation of Page 4 of 38 A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 4 Bak/Bax-like proteins. In the displacement model, the multidomain proteins are neutralized by the anti-apoptotic Bcl-2 family members in healthy cells [16, 18] . Upon apoptosis induction, BH3-only proteins bind to the anti-apoptotic ones thereby displacing Bax or Bak allowing them to be activated through spontaneous self-oligomerization.
The direct activation or hierarchical model discernes BH3-only protein activators (Bim, Bid, and sometimes Puma) and sensitizers (Bad, Bik, Bmf, Noxa) [19, 20] . The former bind to all anti-apoptotic proteins with similar affinity as well as to the pro-apoptotic multidomain proteins whereas the latter do not interact with Bax/Bak-like proteins. Moreover, sensitizer BH3-only proteins display distinct binding preferences to the anti-apoptotic ones. So associated Noxa with Mcl-1 and A1 only while Bad interacts with Bcl-2 and Bcl-xL. In healthy cells, the activators are sequestered by the anti-apoptotic proteins. A certain apoptotic stimulus activates distinct set of sensitizer proteins which, in turn, bind their preferred antiapoptotic partners. The activator proteins, when released from their sequestration, bind to the Bax/Bak-like proteins to induce their oligomerization.
Our previous investigations have shown that Celecoxib induced apoptosis through the Noxa/Mcl-1 axis in Jurkat T cell lymphoma cells leading to downregulation of Mcl-1 [7] . The depletion of Mcl-1 protein levels was sufficient to induce apoptosis in this cell system. Interestingly, overexpression of Bcl-xL but not Bcl-2 could prevent induction of apoptosis in response to Celecoxib [7, 11] . The mechanisms which lead to specific neutralization of Bcl-2 remain elusive. Because of their high sequence homology, Bcl-2 and Bcl-xL were thought to fulfill a redundant protective function. Their binding affinities to other BH3-only proteins are similar but they might also interact with specific partner [21, 22] .
In this present investigation, we examined the mechanism leading to neutralization of Bcl-2 but not the closely related Bcl-xL during Celecoxib-induced apoptosis in Jurkat T cells. Downregulation of activator BH3-only proteins Bim and Puma by siRNA revealed that their presence is not essential for mitochondrial permeabilization and apoptosis induction by 5 Celecoxib. Nor was the activator BH3-only protein Bid which was converted into the apoptotic truncated Bid (tBid) by caspases downstream of m dissipation. We also excluded the involvement of Nur77/TR3 which targets Bcl-2 but not Bcl-xL to transfer it from an anti-apoptotic molecule into a pro-apoptotic one. However, we found a strong interaction of Mcl-1 and Bcl-xL with Bak in healthy Jurkat Vector control and Bcl-xLoverexpressing cells. A Bcl-2:Bak interaction was observed only when Bcl-2 was overexpressed. When harsher lysis conditions were applied the complex of Bcl-2 and Bak could not be detected any longer while Bcl-xL and Mcl-1 still associated with Bak. The present data clearly show that Bcl-2 cannot replace Bcl-xL in Jurkat T cells during Celecoxibinduced apoptosis.
We concluded that Bcl-xL and Mcl-1 prevented activation of Bak through direct interaction.
When sufficiently expressed, Bcl-xL can substitute for Mcl-1 loss in response to Celecoxib.
Bcl-2, however, which is not able to form high affinity complexes with Bak, fails to inhibit Bak activation after Mcl-1 downregulation.
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Reagents and antibodies
All chemicals were purchased from Sigma-Aldrich (Deisenhofen, Germany) unless otherwise specified. The pan-caspase inhibitor zVAD-fmk was purchased from Bachem (Weil/Rhein, Germany). Celecoxib was kindly provided by Pharmacia-Pfizer (Erlangen, Germany).
Following antibodies were used for Western blotting and immunoprecipitation: mouse-anti caspase-9 and rabbit-anti Bak NT from Upstate (Millipore, Schwalbach, Germany), rabbitanti caspase-3, PARP, Mcl-1, Bcl-xL, Bid, Nur77, and Tubulin from Cell Signaling (NEB Frankfurt, Germany), mouse-anti caspase-8 from BioCheck (Münster, Germany), rabbit-anti Puma and Bim from Epitomics (Biomol, Hamburg, Germany), mouse-and rabbit-anti Bcl-2 from Santa Cruz Biotechnology (Heidelberg, Germany), mouse-anti Mcl-1 from Pharmingen (Becton Dickinson, Heidelberg, Germany), mouse-anti Bcl-xL from Transduction Lab (Becton Dickinson, Heidelberg, Germany), mouse-anti Bak (clone TC-100) from Calbiochem (Merck, Darmstadt, Germany), mouse-anti GAPDH from Abcam (Cambridge, UK), and mouse-anti -Actin was obtained from Sigma (Deisenhofen, Germany).
Cells and cell culture
Jurkat E6.1 T-lymphoma cells were from ATCC (Bethesda, Maryland, USA). Jurkat cells stably expressing Bcl-xL or Bcl-2 and the respective Vector control were prepared as described before [7] . Cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (Gibco Life Technologies, Eggenstein, Germany) and maintained in a humidified incubator at 37°C and 5% CO 2 .
7
Transfection with siRNA
Cells were cultured at a low density to ensure log phase growth. For transfection 2x10 6 cells were resuspended in 200 µL RPMI-1640 without phenol red. Shortly before transfection, bim, puma, or non-targeting siRNA was added at indicated concentration. bim and puma ON-TARGET SMARTpool and the siCONTROL NON-TARGETING pool siRNA was purchased from Dharmacon (Chicago, IL, USA). Cells were electroporated in a 4 mm cuvette in an EPI2500 electroporator (Fischer, Heidelberg, Germany) at 370 V for 10 msec.
Immediately after transfection cells were resuspended in 6 mL pre-warmed medium and continued to be cultured as described above. Transfection efficiency and viability was determined by transfecting the cells with 400 nM green fluorescence siRNA (siGLO from Dharmacon, Chicago, IL, USA) followed by propidium iodide exclusion dye and flow cytometric analysis.
Flow cytometric analysis
The mitochondrial membrane potential (m) was analyzed using the m specific dye TMRE (Molecular Probes, Mobitech, Göttingen, Germany). At the indicated time points 
Immunoprecipitation
Cells were lysed as described above using either 1% CHAPS or 1% Triton X-100. The protein concentration was adjusted to 2 mg/mL. 5 µg antibody and 50 µL slurry Dynabeads suspension (Dynal/Invitrogen, Karlsruhe, Germany) were added to 750 µL lysate. After the precipitation for 3h at 4°C the beads were washed thrice with 300 µL lysis buffer containing 0.2% of the respective detergent. Proteins were eluted by boiling the beads for 5 min in 100 µL SDS sample buffer with -Mercaptoethanol. 30 µL were separated by SDS gel 9 electrophoresis before detection by Western blotting as described above. Unless specified, immunoprecipitation studies were always performed in presence of the detergent CHAPS. The downregulation of Mcl-1 is essential for Celecoxib-induced apoptosis [7] . We observed a drastic reduction of Mcl-1 protein levels as early as 3 h after treatment with 75 µM Celecoxib whereas levels of Bcl-2, Bcl-xL, and Bak remained unchanged (Fig. 1D ). The decline of Mcl- (Fig. 2C ).
Role of activator BH3-only proteins during Celecoxib-induced apoptosis
So far, the results from this experiments confirm previous observations demonstrating the early downregulation of Mcl-1 during Celecoxib-induced apoptosis, the protection by Bcl-xL overexpression and the lack thereof by Bcl-2 overexpression [7, 12] . To explore the mechanism of Celecoxib-induced apoptosis further, BH3-only proteins of the Bcl-2 family and their preferred interaction partners were analyzed. The focus was on the activator BH3-only proteins which include Bid, Bim and sometimes Puma because a direct interaction of activator BH3-only proteins with Bax/Bak is thought to be prerequisite for activation of the multi-domain proteins. According to the sequestration model the binding preferences of Bcl-2 and Bcl-xL to different BH3-only proteins might change during Celecoxib-induced apoptosis.
Thus, the expression levels of the three BH3-only proteins were examined ( Fig. 2A ).
Bim is expressed as an extra large, a large, or a small splice variant (Bim EL , Bim L , and Bim S respectively). Puma is expressed as Puma- and Puma  whereas Bid is expressed in an inactive p22 pro-form in healthy Jurkat cells which needs to be processed into a p15 fragment to be activated during apoptosis ( Fig. 2A) .
The protein levels of Bim remained unchanged during Celecoxib-induced apoptosis, but a strong reduction of pro-apoptotic Puma levels and cleavage of Bid were observed in Jurkat
Vector and Jurkat Bcl-2 cells ( Fig. 2A ). Since both of the events correlated with caspase activation, we tested whether the pan-caspase inhibitor zVAD could abrogate Bid cleavage and Puma decline. Treatment with zVAD blocked Celecoxib-induced exposure of Annexin V Furthermore, zVAD interfered with caspase-9, caspase-3, and caspase-8 activation as well as PARP and Bid cleavage and inhibited Puma decline (Fig. 2C) . The results indicate that the regulation of Bid and Puma occurs in the executive phase of apoptosis upon caspase activation and plays a minor role before m dissipation.
Full length Bid (p23) has to be processed to a p15 fragment to fully display its pro-apoptotic potential. In contrast, Puma can change its interaction partners before its degradation. To analyze its relevance for Celecoxib-induced apoptosis in Jurkat cells, Puma was downregulated by siRNA. Puma levels were reduced about 50% 72h after electroporation with 1µM siRNA into Jurkat cells (Fig. 3A) . So, 72h after electroporation of 1 µM puma siRNA or the non-targeting control siRNA, the cells were treated with 50-100 µM Celecoxib for 6h. Apoptosis induction (Fig. 3B ) and m dissipation ( Taken together, our experiments excluded a essential or redundant role of Bid, Bim, and Puma in mitochondrial permeabilization during apoptosis induction by Celecoxib.
Nur77/TR3 does not target Bcl-2 during Celecoxib-induced apoptosis
Since none of the examined BH3-only proteins were needed for Celecoxib-induced apoptosis, the different sensitivity, the regulation of Bcl-2 and Bcl-xL by those BH3-only proteins was implausible. There have to be other interaction partners of the anti-apoptotic proteins which explain the different sensitivity of Bcl-2-and Bcl-xL-overexpressing cells towards Celecoxib.
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A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 Recent publications described the protein Nur77/TR3 which specifically binds to Bcl-2 but not Bcl-xL [23] . In a complex with Nur77/TR3, Bcl-2 loses its protective function. Thus, in the next set of experiment we examined the role of Nur77/TR3 during Celecoxib-induced apoptosis. However, an upregulation of Nur77/TR3 in response to Celecoxib was not observed (Fig. 6A ). Neither could we detect an interaction between Nur77/TR3 and Bcl-2 (Fig. 6B) . Thus, an involvement of Nur77/TR3 during Celecoxib-induced apoptosis could be excluded.
Bcl-2 and Bcl-xL differ in their interaction with Bak
Since Bcl-2 and Bcl-xL showed different affinities for Bim, we hypothesized that those two Triton X-100 instead of the mild CHAPS averted complex formation between Bcl-2 and Bak (Fig. 7B) . In contrast, Bcl-xL and Mcl-1 co-precipitated with Bak even under harsher lysis conditions. Similar results were obtained when Triton X-100 was reduced from 1% to 0.2%. 
Discussion:
Members of the Bcl-2 protein family are important regulators of survival and death during apoptosis induction through the intrinsic pathway. Many cytotoxic drugs as well as the COX-2 inhibitor Celecoxib, ionizing radiation, growth factor withdrawal, and severe hypoxia initiate apoptosis through the mitochondrial pathway [11, [24] [25] [26] [27] . Overexpression of antiapoptotic proteins or inefficient activation of the pro-apoptotic ones improves cellular survival and accounts for resistance against diverse anti-cancer therapies.
Here we show that the Celecoxib-induced apoptosis could be blocked by overexpression of 
Celecoxib: an apoptosis-inducing drug
Celecoxib is a selective COX-2 inhibitor which effectively induces apoptosis by a mechanism yet unknown. The inhibitory and cytotoxic effects could be mapped to different structural characteristics of the molecule and therefore occur independently [28] . The mechanism by which Celecoxib induces apoptosis is not well understood. Celecoxib and its derivates without COX-2 inhibitory function were shown to induce aggravated endoplasmatic stress with subsequent caspase activation. Celecoxib and the related OSU-03012 could also interfere with the PKB/Akt survival pathway [29, 30] . Moreover, Celecoxib, but not the other coxibes A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 17 Rofecoxib and Valdecoxib, can inhibit protein translation transiently with subsequent downregulation of short-lived proteins [31] . Previous result in our lab revealed that Celecoxib facilitated a rapid downregulation of the anti-apoptotic Mcl-1. Lowering the expression levels of the anti-apoptotic Mcl-1 was sufficient for apoptosis induction through the intrinsic pathway [7] . In addition, using an antibody in immunoprecipitation studies which recognized preferentially the active conformation of Bak, we now show that Celecoxib induced a rapid activation of Bak in Jurkat Vector and Bcl-2-overexpressing cells but not in Bcl-xLoverexpressing cells.
Bcl-2 and Bcl-xL: similarities and differences
The Bcl-2 protein family was divided into three subgroups according to the similarities in structure and function: the anti-apoptotic proteins which sequester the pro-apoptotic ones, the pro-apoptotic multidomain proteins whose activation is required during intrinsic apoptosis, and the BH3-only proteins which regulate the activation of the multidomain and neutralize the anti-apoptotic ones [17] . Previous publications have shown that the Bcl-2 family members within a subgroup can fulfill a redundant role during apoptosis induction [32, 33] . Newer data, however, point to a more complex mutual regulation of the pro-and anti-apoptotic Bcl-2 family members. Especially the anti-apoptotic Bcl-2 and its close relative Bcl-xL were thought to be exchangeable. Both proteins maintain mitochondrial homeostasis during apoptosis induction in response to ionizing radiation, hypoxia, cytotoxic drugs, and growth factor withdrawal, whereas both proteins did not affect death receptor induced apoptosis [24, 25, [34] [35] [36] . Despite their similarities, Bcl-2-and Bcl-xL-deficient mice have a different phenotype indicating the regulation of distinct processes [37, 38] . Expression of either Bcl-2
or Bcl-xL in hematopoietic progenitor cells commits to differentiation to erythroid or myolid cells respectively [39] . Also, a switch of expression was observed during tumor progression in A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 melanoma cells when Mcl-1 and Bcl-xL were up-regulated whereas Bcl-2 was downregulated [40] .
Our data emphasize the differences between the similar Bcl-2 and Bcl-xL showing that overexpression of Bcl-xL but not Bcl-2 inhibited Celecoxib-induced apoptosis in Jurkat T lymphoma cells.
Role of Nur77/TR3 during Celecoxib-induced apoptosis
The aim of the present study was the analysis of the mechanism leading to neutralization of Bcl-2 but not Bcl-xL during Celecoxib-induced apoptosis. In this regard, the specific interaction of the orphan nuclear receptor Nur77/TR3 was described. In response to some anti-neoplastic drugs, Nur77/TR3 translocates from nucleus to mitochondria where it interacts with Bcl-2 transforming the anti-apoptotic molecule into a pro-apoptotic one [21] . Nur77 is expressed and upregulated in response to phorbol acetate and calcium ionophore in Jurkat cells [23] . Although having confirmed the expression of Nur77/TR3 protein in Jurkat cells, neither an upregulation of the orphan receptor nor its binding to Bcl-2 was observed during Celecoxib-induced apoptosis. Thus, the lack of protection of Bcl-2 during Celecoxib-induced apoptosis was not due to an interaction of Bcl-2 with Nur77/TR3.
BH3-only proteins during Celecoxib-induced apoptosis
The different protective properties of Bcl-2 and Bcl-xL might also be explained by distinct binding preferences to other Bcl-2 family members. Bcl-2 and Bcl-xL bind to the BH3-only proteins Bad and Bmf whereas they do not interact with Noxa [18, 41] . In this regard, the two survival-promoting proteins differ completely from the anti-apoptotic Bcl-2 family members
Mcl-1 and A1 which display complementary binding preferences. In contrast, activated Bid associates rather with Bcl-xL than with Bcl-2 [18] . Bid must be cleaved by caspases to become activated. During apoptosis induction through the extrinsic pathway, caspases are 19 activated at the death receptor signaling complex prior to m dissipation whereas, during induction of intrinsic apoptosis, they become activated after m dissipation [24, 42] . Since the pan-caspase inhibitor blocked Bid activation without affecting Celecoxib-stimulated m dissipation we concluded that Bid plays no role in initial mitochondrial permeabilization.
Moreover, due to the low-affinity binding to Bcl-2, it is unlikely that tBid neutralized only Bcl-2 during Celecoxib-induced apoptosis [18] .
Puma was described as a BH3-only protein with broad binding spectrum to all anti-apoptotic proteins [41] . Although it is expressed in healthy Jurkat cells, we did not detect any association of Puma with anti-apoptotic proteins or with Bak during Celecoxib-induced apoptosis. Interestingly, Puma is downregulated during Celecoxib-induced apoptosis. The downregulation of Puma was caspase-dependent since it was blocked by the pan-caspase inhibitor zVAD. Thus, the decline of Puma is rather a consequence of apoptosis induction by Celecoxib and of no importance for the initial mitochondrial permeabilization.
Like Puma, Bim was described to have a similar broad binding spectrum to other antiapoptotic Bcl-2 family members [18, 41] . In our cell system, however, Bim preferred Bcl-2 to
Mcl-1 and Bcl-xL. Although Bim is released from its sequestration by Mcl-1 and Bcl-xL during Celecoxib-induced apoptosis, the interaction between Bcl-2 and Bim was not altered during the course. Binding of Bim to Bak in response to Celecoxib was not observed in our cell system. Moreover, siRNA-mediated downregulation of Bim and Puma showed convincingly that neither Bim nor Puma were essential for Celecoxib-induced apoptosis. In contrast, silencing of Bim or Puma improved the survival or Jurkat cells after growth factor withdrawal ( Fig. S2) which is in accordance with observations made earlier [32, 43, 44] .
Taken together, our data indicate that the BH3-only proteins Puma, Bid, and Bim are dispensable for the initial mitochondrial permeabilization during Celecoxib-induced apoptosis.
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Interaction with Bak during Celecoxib-induced apoptosis
Since the interaction between anti-apoptotic Bcl-2 family members and activator BH3-only proteins is of minor importance, we propose the displacement model for Celecoxib-induced apoptosis. This model suggests a sequestration of multidomain proteins by the anti-apoptotic
Bcl-2 family members [15, 18, 45, 46] . Binding of the appropriate BH3-only proteins to antiapoptotic ones displaces the Bax/Bak-like proteins allowing their activation.
Jurkat T lymphoma cells do not express Bax but Bak [12, 47] . Thus, the activation of Bak is essential for Celecoxib-induced apoptosis [13] . Our data show an interaction of Bak with
Mcl-1 or Bcl-xL in Jurkat Vector as well as in the Bcl-2 and Bcl-xL-overexpressing cells.
Using mild lysis condition, Bcl-2:Bak complexes were also detected in Bcl-2-overexpressing cells. However, the association of Mcl-1 or Bcl-xL with Bak was obviously different from that of Bcl-2 with Bak. In contrast to Bcl-2, Bcl-xL and Mcl-1 form complexes even under harsher lysis conditions when 0.2% and 1% Triton X-100 was used suggesting a much stronger interaction between the latter ones and Bak than between Bcl-2 and Bak.
The use of Triton X-100 is not unproblematic. Previous publications showed that immunoprecipitation of Bax and the heterodimerization with anti-apoptotic proteins depends on the detergent used [48] . In addition, Hsu and Youle detected a heterodimerization of Bax with Bcl-2 and Bcl-xL in presence of Triton X-100 but not CHAPS [48] . Contrary to this previous publication, using different concentrations of Triton X-100, our results show that the detergent did not facilitate the binding of the anti-apoptotic Mcl-1 and Bcl-xL to Bak but prevented interaction between Bcl-2 and Bak. Interestingly, Bak was easily precipitated in presence of Triton X-100, and the amount of precipitated Bak did not change over time after treatment with Celecoxib (data not shown). In presence of CHAPS, in contrast, we were hardly able to precipitate Bak in healthy cells. Probably, Triton X-100 interfered with intramolecular interactions of Bak facilitating the exposure of its N-terminus and, therefore, its precipitation with an antibody recognizing the N-terminus. This effect was not observed 21 when the milder detergent CHAPS was used. The N-terminal exposure is a step during Bak activation that precedes Bak oligomerization. In this case, Triton X-100 would allow the association of Mcl-1 and Bcl-xL, but not Bcl-2, with a "partially activated" Bak.
The specificity of Bak for Mcl-1 and Bcl-xL was described earlier [49, 50] . Both publications did not detect any interaction of Bcl-2 with Bak. Thus, Mcl-1 and Bcl-xL protected from apoptosis by sequestration of the pro-apoptotic Bak whereas Bcl-2 did not. Yet, Bcl-2 appears to use other mechanism to protect from apoptosis induced by overexpression of Bax and Bak [50] . Interestingly, our Jurkat cells overexpressing Bcl-2 and Bcl-xL also inhibited apoptosis induction in response to ionizing radiation in earlier experiments [24, 51] . Although Bcl-2 is not capable of effective Bak sequestration, still it could bind to and neutralize other proapoptotic BH3-only family members including Bim, Puma, Bad, and Bmf.
Regarding our data, we suggest following mechanisms for Celecoxib-induced apoptosis: in Overexpression of Bcl-2 fails to inhibit Celecoxib-induced apoptosis because of inaptness to interact with Bak. The different association preferences of Bcl-2 and Bcl-xL with other proapoptotic Bcl-2 family members observed in our experiments allow the conclusion that BclxL and Bcl-2 use different mechanisms to protect from apoptosis in response to distinct stimuli.
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Silencing of Bim and Puma protected Jurkat cells from apoptosis (A) and dissipation of the mitochondrial membrane potential (B) after serum withdrawal.
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